Summary
Goodwin Procter is the lead sponsor of this annual event.
For more information about, the BIOCOM Annual “Celebration of Life” Dinner, click here.
Related Content
- Big Molecule WatchApril 23, 2024
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar
- Big Molecule WatchApril 22, 2024
DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing
- Big Molecule WatchApril 22, 2024
Federal Circuit Dismisses Appeals in Regeneron v. Mylan (Aflibercept) BPCIA Litigation
- AlertApril 22, 2024
The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years
- Big Molecule WatchApril 19, 2024
Fresenius Kabi Announces Launch of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRA
- Big Molecule WatchApril 18, 2024
Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigation
- Big Molecule WatchApril 17, 2024
MDL Panel Grants Transfer of Aflibercept BPCIA Case
- Big Molecule WatchApril 11, 2024
FDA Approves BMS and J&J CAR-T Cell Therapies for the Earlier Treatment of Multiple Myeloma
- Press ReleaseApril 23, 2024
Allurion Technologies Completes $48 Million Convertible Senior Secured Note Financing with RTW Investments
- Press ReleaseApril 22, 2024
Sound Bioventures joins £19 Million Financing of Theolytics
- Awards and RankingsApril 18, 2024
Goodwin is Number One in the Q1 2024 League Table Rankings
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
- Press ReleaseApril 16, 2024
Goodwin Represents the Underwriters in PACS Group $450 Million IPO
- Press ReleaseApril 15, 2024
Goodwin Advises Exclusive Placement Agent in Acrivon Therapeutics’ $130 Million Private Placement
- Press ReleaseApril 10, 2024
Alpine Immune Sciences To Be Acquired by Vertex Pharmaceuticals For $4.9 Billion